GlassScriptPhysician profile
Parvez S Mantry
NPI 1770528697
$958,424.77
in general payments reported to CMS, 2019-2025
60 companies · $302K in 2025
The $302K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123K · 2020: $51K · 2021: $73K · 2022: $106K · 2023: $97K · 2024: $207K · 2025: $302K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $354K · Consulting Fee: $149K · Travel and Lodging: $43K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $37K · Food and Beverage: $18K · Honoraria: $4,725 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $354,277.13 |
| Consulting Fee | $148,876.00 |
| Travel and Lodging | $42,924.13 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $37,225.00 |
| Food and Beverage | $17,615.36 |
| Honoraria | $4,725.00 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $199,075.43 | 2021-2025 | Wegovy, Ozempic |
| Madrigal Pharmaceuticals | $153,855.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $121,388.41 | 2019-2025 | Livdelzi, Vemlidy, Epclusa |
| Intercept Pharmaceuticals, INC. | $105,172.73 | 2019-2025 | Ocaliva |
| Eisai INC. | $97,161.96 | 2019-2025 | |
| Abbvie INC. | $90,098.10 | 2019-2025 | |
| Amgen INC. | $42,209.14 | 2024-2025 | Uplizna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38,707.85 | 2019-2025 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $33,527.18 | 2024-2025 | Iqirvo, Bylvay |
| Sirtex Medical INC | $20,932.66 | 2019-2023 | Sir-Spheres Microspheres |
| Shionogi INC | $13,027.04 | 2019-2020 | |
| Boston Scientific Corporation | $12,218.81 | 2021-2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial), Therasphere Y90 Glass Microspheres 10 Gbq, General - Biliary Devices |
| W. L. Gore & Associates, INC. | $9,486.04 | 2024 | Viatorr Endoprosthesis, Viatorr Tips Endoprosthesis W/ Controlled Expansion, Gore Viatorr Tips Endoprosthesis |
| Janssen Biotech, INC. | $4,241.33 | 2019 | |
| Mallinckrodt Enterprises LLC | $4,181.22 | 2019 |
Show all 46 companies
14 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parvez Mantry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.